SNSE — Sensei Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $10.69m
- -$29.81m
- 29
- 54
- 18
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.28 | ||
| Price to Tang. Book | 0.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.71% | ||
| Return on Equity | -58.4% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Directors
- John Celebi PRE (49)
- Erin Colgan SVF (40)
- Robert Pierce CSO (56)
- Marie-Louise Fjaellskog OTH (56)
- Anupama Hoey OTH (50)
- Kristian Humer DRC (46)
- Samuel Broder IND
- Bob Holmen IND (57)
- James Peyer IND (34)
- Thomas Ricks IND (67)
- Deneen Vojta IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 1st, 2017
- Public Since
- February 4th, 2021
- No. of Shareholders
- 196
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 25,208,068
- Address
- 1405 Research Blvd, Suite 125, ROCKVILLE, 20850
- Web
- https://www.senseibio.com/
- Phone
- +1 2402438000
- Contact
- Michael Biega
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SNSE
Sensei Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 Sensei Biotherapeutics Inc Earnings Release
Similar to SNSE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Sensei Biotherapeutics share price?
As of Today at 23:10 UTC, shares in Sensei Biotherapeutics are trading at $0.42. This share price information is delayed by 15 minutes.
How has the Sensei Biotherapeutics share price performed this year?
Shares in Sensei Biotherapeutics last closed at $0.42 and the price had moved by -74.29% over the past 365 days. In terms of relative price strength the Sensei Biotherapeutics share price has underperformed the S&P500 Index by -76.82% over the past year.
What are the analyst and broker recommendations for Sensei Biotherapeutics?
The overall consensus recommendation for Sensei Biotherapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sensei Biotherapeutics dividend yield?
Sensei Biotherapeutics does not currently pay a dividend.
Does Sensei Biotherapeutics pay a dividend?
Sensei Biotherapeutics does not currently pay a dividend.
When does Sensei Biotherapeutics next pay dividends?
Sensei Biotherapeutics does not currently pay a dividend.
How do I buy Sensei Biotherapeutics shares?
To buy shares in Sensei Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sensei Biotherapeutics?
As of the previous close price of $0.42, shares in Sensei Biotherapeutics had a market capitalisation of $10.69m.
Where are Sensei Biotherapeutics shares listed?
Here are the trading details for Sensei Biotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNSE
What kind of share is Sensei Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Sensei Biotherapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sensei Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sensei Biotherapeutics is $4.00. That is 842.95% above the last closing price of $0.42.
Analysts covering Sensei Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.75 for the next financial year.
Find out moreWhat is the trend in the Sensei Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sensei Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -13.05%.
As of the last closing price of $0.42, shares in Sensei Biotherapeutics were trading -15.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sensei Biotherapeutics PE Ratio?
The Sensei Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sensei Biotherapeutics?
Sensei Biotherapeutics' management team is headed by:
- John Celebi - PRE
- Erin Colgan - SVF
- Robert Pierce - CSO
- Marie-Louise Fjaellskog - OTH
- Anupama Hoey - OTH
- Kristian Humer - DRC
- Samuel Broder - IND
- Bob Holmen - IND
- James Peyer - IND
- Thomas Ricks - IND
- Deneen Vojta - IND